ERBB2 and breast carcinoma: The scenery of mutations found in tumors is vast and difficult to fully characterize in the clinical setting, as it is difficult to understand and justify why specific tumors express specific receptors, such as breast cancer cells and HER-2, but since the arsenal of pharmacological options is developed, targets for these molecules are searched in tumors, opening doors for new therapies.